• Y Lin, C J Moltzan, D R Anderson, and National Advisory Committee on Blood and Blood Products.
• Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Ontario, Canada. yulia.lin@sunnybrook.ca
• Transfus Med. 2012 Dec 1;22(6):383-94.

AbstractIn 2006, the Canadian National Advisory Committee on Blood and Blood Products (NAC) developed a transfusion policy framework for the use of off-label recombinant factor VIIa (rFVIIa) in massive bleeding. Because the number of randomised controlled trials has doubled, the NAC undertook a review of the policy framework in 2011. On the basis of the review of 29 randomised controlled trials, there remains little evidence to support the routine use of rFVIIa in massive bleeding. Mortality benefits have not been demonstrated. Contrarily, an increase in arterial thromboembolic events has been observed with the use of off-label rFVIIa. Given the absence of evidence of benefit and with evidence of the risk of harm, the NAC recommends that recombinant VIIa no longer be used for the off-label indications of prevention and treatment of bleeding in patients without haemophilia.© 2012 The Authors. Transfusion Medicine © 2012 British Blood Transfusion Society.

12 keywords...

hide…